Information Provided By:
Fly News Breaks for July 28, 2016
JAZZ
Jul 28, 2016 | 13:03 EDT
BMO Capital analyst Gary Nachman views the Patent Trial and Appeal Board's denial of Amneal's request to institute an inter partes review as a "significant positive" for Jazz Pharmaceuticals since it validates one of the longest dated patents on Xyrem. The development should provide Jazz with additional leverage in potential settlement discussions with first-filer Hikma/Roxane, Nachman tells investors in a research note. The analyst has an Outperform rating on Jazz with a $190 price target.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.